Labaran Waya

Cire Sabon Nazari don Maganin ALS

Written by edita

NeuroSense Therapeutics Ltd. a yau ta sanar da cewa ta sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) don fara nazarin harhada magunguna na PrimeC a cikin batutuwan manya masu lafiya. PrimeC wani labari ne na tsawaita-saki na baka wanda ya ƙunshi ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun haɗin magunguna guda biyu da FDA ta amince: ciprofloxacin da celecoxib. An ƙirƙira PrimeC don haɗa kai da wasu mahimman hanyoyin dabarun amyotrophic lateral sclerosis (ALS) waɗanda ke ba da gudummawa ga lalatawar neuron neuron, kumburi, tara ƙarfe da ƙarancin ƙa'idar RNA don yuwuwar hana ci gaban ALS.     

An ba PrimeC Nazarin Magungunan Marayu ta FDA da Hukumar Kula da Magunguna ta Turai (EMA). NeuroSense ya kammala nazarin asibiti na Phase IIa wanda ya sami nasarar cimma amincinsa da ingancin ƙarshensa ciki har da rage ayyukan aiki da tabarbarewar numfashi da mahimman canje-canje a cikin alamomin nazarin halittu masu alaƙa da ALS waɗanda ke nuna ayyukan nazarin halittu na PrimeC. Kamfanin yana shirin ƙaddamar da wani mataki na IIb makafi biyu-makafi mai sarrafa nazarin ƙasa da ƙasa a cikin Q2 2022 tare da ingantaccen kashi da ingantaccen tsari na musamman.

Nazarin pharmacokinetic (NCT05232461) shine alamar buɗewa na Mataki na I, bazuwar, kashi-kashi ɗaya, jiyya guda uku, nazarin tsaka-tsakin lokaci uku don kimanta tasirin abinci akan bioavailability na PrimeC idan aka kwatanta da bioavailability na allunan ciprofloxacin da aka gudanar tare. da celecoxib capsules a cikin manya masu lafiya guda 12 a cikin Amurka.

"Bayani daga binciken mu na asibiti na Phase IIa ya tabbatar da cewa PrimeC wani labari ne na farfadowa tare da yuwuwar taimakawa mutanen da ke da ALS da kuma magance kasuwar dala biliyan 3 da ke buƙatar ingantaccen magani," in ji shugaban NeuroSense Alon Ben-Noon. "Yayin da muke shirin fara karatunmu na Mataki na IIb a cikin 'yan watanni masu zuwa, makasudin binciken mu na harhada magunguna a karkashin FDA IND shine samar da ƙarin bayanai kan bioavailability na PrimeC kamar yadda ya shafi cin abinci a cikin mutane masu lafiya. Mun himmatu sosai don inganta rayuwar mutanen da ke tare da ALS kuma muna alfaharin samar da wani sabon magani mai mahimmanci don magance wannan hadadden cuta. " 

NeuroSense kwanan nan ya sanar da mataki na uku na haɗin gwiwa tare da Babban Asibitin Massachusetts a Boston a kan novel Neuron-Derived Exosomes (NDEs) don ƙara ƙayyade sauye-sauyen halittu a cikin cututtuka masu alaka da ALS da tasirin PrimeC akan maƙasudin da suka dace. Ana sa ran sakamako daga wannan binciken Q2 2022.

NeuroSense kuma yana haɓaka shirye-shirye a cikin cutar Alzheimer don ɗan takararta na magani CogniC da cutar Parkinson don StabiliC. Ana sa ran bayanai daga ainihin karatun H2 2022, kuma bin biyayyar IND ga FDA, NeuroSense yana tsammanin fara karatun asibiti a cikin waɗannan alamun a cikin H1 2023.

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

1 Comment

  • Sanarwa Jama'a>>>Maganin da aka dade ana jira na HERPES, HIV, HPV, HSV1&2, CIWON SUGA, CANCER, CIWON FARji ya kare. Dokta Osato ya zo ne domin ya ceci dan Adam da maganinsa na ganye kuma ana ba shi shawarar a duk fadin duniya don kyakkyawan aikin da yake yi a rayuwar mutane ta hanyar magance su daga cututtuka / ƙwayoyin cuta daban-daban. Ya kuma warkar da ni daga al'aura Herpes da maganin ganye. Idan kuna buƙatar maganin, tuntuɓi Dr Osato akan imel ɗin sa: [email kariya] ko WhatsApp shi a +2347051705853. Kar ki mutu kiyi shiru kina tunanin babu maganin ciwon 1&2. Tuntuɓi Dr Osato a yau kuma ku kawar da wannan mummunar cuta / ƙwayar cuta a jikin ku. Gidan yanar gizon sa shine osatoherbalcure.wordpress.com

Share zuwa...